Payment overview · 2025
General Payments
$237.47
10 reported records · 9 companies
Healthcare provider profile · identity verified
John D. Adams, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · LONG BEACH, CA · NPI 1801852900
Verified facts
What the public records show
CMS Open Payments records show John D. Adams, D.O. received $237.47 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.04 | 18.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.13 | 13.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.79 | 11.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.67 | 11.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.74 | 10.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.24 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.71 | 8.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.79 | 7.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.36 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $237.47 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.13 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 187 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 216 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 305 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
187 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
216 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
305 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
70 | 21 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
199 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1776 | 410 |
| Amlodipine Besylate | Amlodipine Besylate | 1022 | 233 |
| Gabapentin | Gabapentin | 659 | 130 |
| Metformin Hcl | Metformin Hcl | 604 | 157 |
| Losartan Potassium | Losartan Potassium | 586 | 143 |
| Lisinopril | Lisinopril | 566 | 119 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 564 | 120 |
| Hydrochlorothiazide | Hydrochlorothiazide | 555 | 123 |
| Furosemide | Furosemide | 513 | 100 |
| Omeprazole | Omeprazole | 499 | 135 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 472 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 452 | 125 |
| Diclofenac Sodium | Diclofenac Sodium | 407 | 121 |
| Potassium Chloride | Potassium Chloride | 398 | 86 |
| Ibuprofen | Ibuprofen | 383 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 327 | 75 |
| Carvedilol | Carvedilol | 309 | 67 |
| Ozempic | Semaglutide | 305 | 59 |
| Famotidine | Famotidine | 279 | 47 |
| Azithromycin | Azithromycin | 277 | 109 |
| Allopurinol | Allopurinol | 276 | 64 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 274 | 56 |
| Simvastatin | Simvastatin | 265 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 258 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 51 |
| Jardiance | Empagliflozin | 216 | 52 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 214 | 36 |
| Naproxen | Naproxen | 211 | 59 |
| Benazepril Hcl | Benazepril Hcl | 205 | 41 |
| Trazodone Hcl | Trazodone Hcl | 200 | 47 |
| Eliquis | Apixaban | 199 | 49 |
| Farxiga | Dapagliflozin Propanediol | 187 | 49 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 186 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 185 | 36 |
| Meloxicam | Meloxicam | 174 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 54 |
| Januvia | Sitagliptin Phosphate | 165 | 36 |
| Lorazepam | Lorazepam | 161 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 152 | 37 |
| Baclofen | Baclofen | 150 | 29 |
| Finasteride | Finasteride | 140 | 32 |
| Spironolactone | Spironolactone | 140 | 21 |
| Tramadol Hcl | Tramadol Hcl | 134 | 41 |
| Clonidine Hcl | Clonidine Hcl | 133 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 42 |
| Montelukast Sodium | Montelukast Sodium | 132 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 35 |
| Mupirocin | Mupirocin Calcium | 125 | 14 |
| Hydrocortisone | Hydrocortisone | 118 | 25 |
| Nifedipine Er | Nifedipine | 118 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 117 | 33 |
| Glipizide | Glipizide | 115 | 23 |
| Atenolol | Atenolol | 112 | 24 |
| Glimepiride | Glimepiride | 112 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 17 |
| Xarelto | Rivaroxaban | 106 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 105 | 22 |
| Alprazolam | Alprazolam | 103 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 96 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 96 | 22 |
| Donepezil Hcl | Donepezil Hcl | 94 | 24 |
| Sertraline Hcl | Sertraline Hcl | 91 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 21 |
| Meloxicam | Meloxicam, Submicronized | 89 | 21 |
| Mounjaro | Tirzepatide | 86 | 16 |
| Carisoprodol | Carisoprodol | 83 | 13 |
| Meclizine Hcl | Meclizine Hcl | 79 | 19 |
| Levetiracetam | Levetiracetam | 77 | 18 |
| Methylprednisolone | Methylprednisolone | 77 | 39 |
| Nystatin | Nystatin | 76 | 14 |
| Prednisone | Prednisone | 76 | 15 |
| Cephalexin | Cephalexin | 74 | 48 |
| Ezetimibe | Ezetimibe | 74 | 19 |
| Ondansetron Odt | Ondansetron | 72 | 12 |
| Fluconazole | Fluconazole | 71 | 20 |
| Rybelsus | Semaglutide | 70 | 21 |
| Metformin Hcl Er | Metformin Hcl | 69 | 18 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 68 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 12 |
| Pregabalin | Pregabalin | 67 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 14 |
| Lansoprazole | Lansoprazole | 66 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 35 |
| Nitroglycerin | Nitroglycerin | 65 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 65 | 17 |
| Azelastine Hcl | Azelastine Hcl | 64 | 11 |
| Linzess | Linaclotide | 63 | 15 |
| Terazosin Hcl | Terazosin Hcl | 63 | suppressed |
| Topiramate | Topiramate | 63 | suppressed |
| Amoxicillin | Amoxicillin | 62 | 32 |
| Entresto | Sacubitril/Valsartan | 62 | 11 |
| Methocarbamol | Methocarbamol | 62 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 17 |
| Risperidone | Risperidone | 61 | suppressed |
| Fenofibrate | Fenofibrate | 58 | suppressed |
| Humalog | Insulin Lispro | 58 | suppressed |
| Procto-Med Hc | Hydrocortisone | 58 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 57 | 21 |
| Ketoconazole | Ketoconazole | 55 | 17 |
| Lidocaine | Lidocaine | 54 | 14 |
| Chlorthalidone | Chlorthalidone | 52 | 13 |
| Mupirocin | Mupirocin | 52 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | suppressed |
| Bumetanide | Bumetanide | 48 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | 14 |
| Latanoprost | Latanoprost | 48 | 13 |
| Memantine Hcl | Memantine Hcl | 46 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | suppressed |
| Celecoxib | Celecoxib | 45 | 17 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Loperamide | Loperamide Hcl | 43 | 12 |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 42 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 41 | 18 |
| Acyclovir | Acyclovir | 39 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Colchicine | Colchicine | 37 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 32 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | 16 |
| Estradiol | Estradiol | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 15 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Norgesic Forte | Orphenadrine/Aspirin/Caffeine | 28 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 15 |
| Ibu | Ibuprofen | 27 | 11 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 24 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Permethrin | Permethrin | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 23 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Naproxen Sodium Er | Naproxen Sodium | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Aripiprazole Odt | Aripiprazole | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Bicalutamide | Bicalutamide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Zolmitriptan Odt | Zolmitriptan | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $237.47 · 10 records | Novo Nordisk Inc | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, FARXIGA, GARDASIL 9, JARDIANCE, M-M-R II, Omnipod, Ozempic, PREVNAR 20, REXULTI, Rybelsus, SHINGRIX, VRAYLAR, Wegovy | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error